China VenturesChina Ventures 中华创投协会DEAL MARKETPLACE
Health & Bio · Beta

HQ Science

Rapid molecular diagnostics — results in hours, not weeks.

BetaListings are in beta: details come from the parties and are not independently verified. Read the disclaimer.
Raising£1.5m
StageSeed
RegionUK & Europe
Valuation
TractionMHRA-authorised for commercial sale in the UK; clinical feasibility completed with the Oscar Lambret Centre; signed LOIs with five NHS Trusts and Oscar Lambret (France); UK Health Security Agency spin-out.
The business

What it does

HQ Science is a UK Health Security Agency spin-out commercialising a point-of-care molecular diagnostics platform that combines third-generation sequencing with AI to deliver results within 24 hours at roughly half the cost of current tests. The device is authorised for commercial sale in the UK and registered with the MHRA, has completed a clinical feasibility study with the Oscar Lambret Centre in France, and has signed LOIs with five NHS Trusts and Oscar Lambret. Ready panels include Luminal A/B breast cancer diagnostics and radiological emergency triage, with sepsis in development. The £1.5m EIS seed round funds 24 months of UK and EU commercialisation, ISO 15189 accreditation and rollout across the five NHS Trusts.

Members only

Login to see details

Sign in to see the summary, the evidence and use of funds for HQ Science. Membership is free.

We never publish contact details on the site. After approval the system will make an intelligent match.